reports of the histological changes in lichen sclerosus during pimecrolimus or tacrolimus treatment. There is a small lifetime risk (3-5%) in anogenital lichen sclerosus for the development of squamous cell carcinoma and recently, there has been concerns about the development of cancers and lymphomas in patients using these preparations.

**Methods:** 29 outpatients with histologically confirmed, active LS were recruited to this study with two aims. First we evaluated the effectiveness of pimecrolimus treatment to LS. Secondly, we evaluated the histological changes during pimecrolimus treatment.

**Results:** All 29 patients completed the follow-up period. 69% (20/29) were in complete remission including relief from itch, pain and inflammation. There were no systemic adverse reactions. In vulvar differentiated intraepithelial neoplasia (d-VIN), which is a postulated precursor lesion for LS-associated vulvar squamous cell carcinoma (SCC), the atypical keratinocyte p53 expression in a typical finding. Surprisingly, the expression of p53 was down-regulated during pimecrolimus treatment.

**Conclusions:** In our opinion, patient-applied 1% pimecrolimus cream is safe and effective for the treatment of LS. The decrease of p53 staining during pimecromus treatment is best explained for the decrease of ischaemic stress response due to poor oxygenation, vasculitis and inflammation during healing process.

**Keywords:** Lichen sclerosus, pimecrolimus, immunomodulation, p53, hypoxic stress response.

**448 EVALUATION OF THE ESTROGENIC EFFECT OF NIGELLA SATIVA USING THE RAT MODELS OF UTEROTROPHIC ASSAY**

S. Parhizkar1, L.A. Latiff1, A.R. Sabariah2, M.A. Dollah1, S.T.S. Hassan1, P. Hanachi2, R. Ibrahim3. 1University Putra Malaysia, Community Health-Faculty of Medicine and Health Sciences, Serdang, Malaysia; 2University Putra Malaysia, Pathology Department-Faculty of Medicine and Health Sciences, Serdang, Malaysia; 3University Putra Malaysia, Biomedical Department-Faculty of Medicine and Health Sciences, Serdang, Malaysia

**Introduction:** nigella sativa (Black Seed) have been used as a traditional medicine for the treatment of a variety of sicknesses as well as health status including increase of milk flow and regulation of menstruation in the female.

**Objectives:** Evaluation of estrogenic activity of Nigella sativa using menopause induced rat models.

**Methods:** Nigella sativa was administrated orally as a supplement to chow pellet at different doses of 300, 600 and 1200 mg/kg for 21 days to ovariectomized (OVX) rats and were compared to either Conjugated Equine Pellet at different doses of 300, 600 and 1200 mg/kg for 21 days to control. Estrogen-CEE (0.2mg/kg) as positive or distilled water (1ml) as negative control.

**Results:** Treatment with Nigella sativa resulted to a significant increase in uterine weight as compared to control OVX with altering the serum estrogen- receptors with enhancing the endogenous estrogen levels.

**Conclusions:** Nigella sativa showed the desired effects on rats’ reproductive performance, thereby indicating its beneficial roles in the treatment of the postmenopausal symptoms.

**Keywords:** Nigella sativa, Estrogenic Effects, Uterotropic Assay, Ovariectomized Rats

**449 EFFECTIVENESS OF TWO REGIMES OF GLUCOSAMINE AND CHONDROTIN FOR TREATMENT OF PAIN SYNDROME IN PATIENT WITH KNEE OSTEOARTHRITIS**

V. Poveroznyuk, N. Gryzovycva, N. Dzerovych, T. Karsevskaya. Institute of Gerontology AMS Ukraine, Department of Clinical Physiology and Pathology of Locomotor Apparatus, Kyiv, Ukraine

**Objectives:** The research was aimed at evaluating the effectiveness of two regimes (continuous and interrupted) of Theraflex (500 mg glucosamine hydrochloride, 400 mg chondroitin sulphate) in patients with knee osteoarthritis. Outcomes evaluated were pain, measures of performance (function, activity of daily living, disability), employment status, range of motion, and patient satisfaction/patient global perceived effects.

**Methods:** The first group included 50 patients (aged 64.5±1.1 years) with knee osteoarthritis (II stage, Kellgren-Lawrence’s classification), who took the drug in continuous regime during 9 months. The second group included 50 patients with the same diagnosis (aged 64.6±1.0 years), who took Theraflex twice during 3 months with 3 months interruption. We examined the patients before the treatment and after 1, 3, 6, 9 and 12 months. Methods of study: Mc-Gill questionnaire, visual-analogical scale (VAS), Lequen’s index, WOMAC, EuroQol-5D, 15-m. test, 6-min. test.

**Results:** After three months of Theraflex’s treatment it was observed a reliable decrease of pain syndrome in both groups by WOMAC, decrease of constraint in movements, improvement of index of everyday activity, VAS, 15-m.test. Examination of patients during 6,9 and 12 months show the effectiveness of both regimes of the therapy. Intensity of pain syndrome and functional activity didn’t differ between the groups.

**Conclusions:** During 1-year period two regimes of Theraflex it was established effective decrease of intensity of the pain syndrome and improvement of everyday activity in patients with knee osteoarthritis. The analgesic effect after taking Theraflex becomes noticeable after three months and quality of life significantly improved in patients of both groups.

**Keywords:** Glucosamine, chondroitin, osteoarthritis.